These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26352777)

  • 1. How we treat systemic light-chain amyloidosis.
    Chaulagain CP; Comenzo RL
    Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Light chain (AL) amyloidosis: update on diagnosis and management.
    Rosenzweig M; Landau H
    J Hematol Oncol; 2011 Nov; 4():47. PubMed ID: 22100031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
    Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
    Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.
    Tandon N; Sidana S; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Fonder AL; Hobbs MA; Hayman SR; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
    Am J Hematol; 2017 Jun; 92(6):549-554. PubMed ID: 28314084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights and modern treatment of AL amyloidosis.
    Chaulagain CP; Comenzo RL
    Curr Hematol Malig Rep; 2013 Dec; 8(4):291-8. PubMed ID: 24026941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked and rapid regression of hepatic amyloid deposition in a patient with systemic light chain (AL) amyloidosis after high-dose melphalan therapy with stem cell transplantation.
    Katoh N; Matsushima A; Kurozumi M; Matsuda M; Ikeda S
    Intern Med; 2014; 53(17):1991-5. PubMed ID: 25175136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future directions in the clinical management of amyloid light-chain amyloidosis.
    Haider S; Ahmad N; Anaissie E; Driscoll JJ
    Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin light chain amyloidosis.
    Merlini G; Comenzo RL; Seldin DC; Wechalekar A; Gertz MA
    Expert Rev Hematol; 2014 Feb; 7(1):143-56. PubMed ID: 24350907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic light chain amyloidosis: an update for treating physicians.
    Merlini G; Wechalekar AD; Palladini G
    Blood; 2013 Jun; 121(26):5124-30. PubMed ID: 23670179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of novel therapies in the treatment of light chain amyloidosis.
    Varga C; Titus SE; Toskic D; Comenzo RL
    Blood Rev; 2019 Sep; 37():100581. PubMed ID: 31167719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
    Weiss BM; Wong SW; Comenzo RL
    Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment strategy for immunoglobulin light chain amyloidosis].
    Fuchida SI
    Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
    Vaxman I; Dispenzieri A; Muchtar E; Gertz M
    Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
    Sanchorawala V
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1131-44. PubMed ID: 25459183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
    Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
    Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.